Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

BackgroundWhile telemedicine has been beneficial in oncology by reducing infectious exposure and improving access for patients with poor functional status, it also has intrinsic limitations, including the inability to perform a physical exam, which could lead to increased downstream utilization in this population at high risk of medical decompensation. We conducted a retrospective cohort study investigating the relationship between telemedicine use in oncology and subsequent outpatient oncology encounters, emergency department (ED) visits, and hospitalizations.MethodsWe included outpatient oncology encounters, including telemedicine and in-person visits, occurring between 1 January 2018 and 31 December 2022 at a large academic health system. Unadjusted descriptive statistics and multiple linear regressions were used to estimate subsequent outpatient oncology visits, ED visits, and hospitalizations within 30 days of an index visit based on modality (telemedicine versus in-person). The multiple regressions were adjusted for various demographic and clinical characteristics, including palliative care visits, baseline utilization, recent chemotherapy, and comorbidities.ResultsOur cohort included 63,722 patients with 689,356 outpatient encounters, of which 639,217 (92.7%) were in-person and 50,139 (7.3%) were telemedicine visits. Patients on average had 0.91 outpatient oncology visits, 0.04 ED visits, and 0.05 hospitalizations within 30 days following an index encounter. In our adjusted analyses, telemedicine was associated with 13.7 fewer downstream outpatient oncology visits (95% CI 12.5-14.9;  < 0.001) per 100 index encounters, 0.7 fewer ED visits (95% CI 0.4-1.0;  < 0.001) per 100 index encounters and 0.9 fewer hospitalizations (95% CI 0.6-1.3;  < 0.001) per 100 index encounters compared to in-person visits.ConclusionsContrary to our hypothesis, oncology patients who had a telemedicine visit had fewer follow-up outpatient oncology encounters, ED visits and hospitalizations after 30 days than those with in-person visits. Future studies should further investigate the efficacy of telemedicine in oncology and outline specific scenarios for appropriate use in this and other populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009617PMC
http://dx.doi.org/10.1177/1357633X241282820DOI Listing

Publication Analysis

Top Keywords

outpatient oncology
20
oncology visits
12
visits
9
oncology
8
downstream utilization
8
large academic
8
academic health
8
health system
8
subsequent outpatient
8
oncology encounters
8

Similar Publications

IntroductionDaratumumab is a therapeutic cornerstone of the management of multiple myeloma, exerting its anti-myeloma activity through targeting of the cell surface glycoprotein CD38 on plasma cells. While originally given intravenously, the subcutaneous formulation, daratumumab hyaluronidase injection (Dara SC), has been associated with non-inferior efficacy and lower infusion-related reaction rates (IRRs) in the treatment of multiple myeloma and light chain amyloidosis. A noted benefit of Dara SC is a short administration time; however, the optimal observation time post injection to ensure patient safety is unclear from the drug labeling.

View Article and Find Full Text PDF

Objective: This study aimed to investigate comorbidity patterns and potential pathogenic mechanisms in patients with Hashimoto's thyroiditis (HT).

Methods: Patients with HT who visited the outpatient clinic of the Thyroid Department at Dongzhimen Hospital, Beijing University of Chinese Medicine, between June 2021 and December 2024 were included. Association rule analysis and logistic regression analysis were performed using SPSS 25.

View Article and Find Full Text PDF

Morning administration of anthracyclines is associated with a lower risk of cancer therapy-related cardiac dysfunction.

Eur Heart J Open

September 2025

Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

Aims: Pre-clinical studies point towards an administration time-dependency of anthracycline-induced cancer therapy-related cardiac dysfunction (CTRCD). This retrospective study aimed to investigate the association between time-of-day of AC administration and CTRCD.

Methods And Results: Patients from two cardio-oncology outpatient clinics, treated with ACs for any malignancy, were included.

View Article and Find Full Text PDF

Purpose: To clarify the preferred timing and contents of early palliative care and preference for continued care delivery among patients with advanced cancer in Japan.

Methods: We conducted an Internet-based anonymous questionnaire survey on adult patients with advanced cancer. We assessed the patients' wishes for palliative care delivered by a team or at outpatient clinics while asymptomatic, as well as the preferred intervention timing and preference for continuing care lifelong.

View Article and Find Full Text PDF

Purpose: The German sector-based healthcare system poses a major challenge to continuous patient monitoring and long-term follow-up, both essential for generating high-quality, longitudinal real-world data. The national Network for Genomic Medicine (nNGM) bridges the inpatient and outpatient care sectors to provide comprehensive molecular diagnostics and personalized treatment for non-small cell lung cancer (NSCLC) patients in Germany. Building on the established nNGM infrastructure, the DigiNet study aims to evaluate the impact of digitally integrated, personalized care on overall survival (OS) and the optimization of treatment pathways, compared to routine care.

View Article and Find Full Text PDF